Replacing the Amsler grid: A new method for monitoring patients with age-related macular degeneration

Ophthalmology

Volumn 110, Issue 5, 2003, Pages 966-970

  Loewenstein, Anat ^a   Malach, Rafael ^b   Goldstein, Michaela ^a   Leibovitch, Igal ^a   Barak, Adiel ^a   Baruch, Eli ^a   Alster, Yair ^c   Rafaeli, Omer ^c   Avni, Isaac ^d   Yassur, Yuval ^e  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b Department of Veterinary Resources   (Israel)

^c Notal Vision Ltd   (Israel)

^d Maccabi Eye Institute   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; ATROPHY; AUTOANALYSIS; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE COURSE; EYE FIXATION; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; SCOTOMA; SUBRETINAL NEOVASCULARIZATION; VISION TEST; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT;

EID: 0037542838     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(03)00074-5     Document Type: Article

References (26)

1. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-43.
2. Pizzarello LD. The dimensions of the problem of eye disease among the elderly. Ophthalmology 1987;94:1191-5.
3. Bressler NM, Bressler SB. Preventive ophthalmology. Agerelated macular degeneration. Ophthalmology 1995;102: 1206-11.
4. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS report no 8. Age-related Eye Disease Study Research Group. Arch Opthalmol 2001;119:1417-36.
5. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
6. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109: 1109-14.
7. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1994; 112:500-9.
8. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthlamol 1993;111:1200-9.
9. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials - TAP report 1. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group [published erratum appears in Arch Ophthalmol 2000;118:488]. Arch Ophthalmol 1999;117:1329-45.
10. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP report 2. Treatment of Age-Related Macular Degeneration with Photodynam (TAP) Study Group. Arch Ophthalmol 2001;119: 198-207.
11. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1. Verteporfin in Photodynamic Therapy Study Group. Ophthalmology 2001; 108:841-52.
12. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2. Verteporfin in Photodynamic Therapy Study Group. Am J Ophthalmol 2001;131:541-60.
13. Bressler NM, Bressler SB, Gragoudas ES. Clinical characteristics of choroidal neovascular membranes. Arch Ophthalmol 1987;105:209-13.
14. Fine SL. Early detection of extrafoveal neovascular membranes by daily central field evaluation. Ophthalmology 1985; 92:603-9.
15. Fine AM, Elman MJ, Ebert JE, et al. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol 1986;104:513-4.
16. Achard OA, Safran AB, Duret FC, Ragama E. Role of the completion phenomenon in the evaluation of Amsler grid results. Am J Ophthalmol 1995;120:322-9.
17. Wall M, Sadun AA. Threshold Amsler grid testing. Crosspolarizing lenses enhance yield. Arch Ophthalmol 1986;104: 520-3.
18. Roy MS. Vision loss without Amsler grid abnormalities in macular subretinal neovascularization. Ophthalmologica 1985;191:215-7.
19. Schuchard RA. Validity and interpretation of Amsler grid report. Arch Ophthalmol 1993;111:776-80.
20. Gilbert CD, Wiesel TN. Receptive field dynamics in adult primary visual cortex. Nature 1992;356:150-2.
21. Parkes L, Lund J, Angelucci A, et al. Compulsory averaging of crowded orientation signals in human vision. Nat Neurosci 2001;4:739-44.
22. Kaas JH, Krubitzer LA, Chino YM, et al. Reorganization of retinotopic cortical maps in adult mammals after lesions of the retina. Science 1990;248:229-31.
23. Westheimer G. The spatial sense of the eye. Proctor lecture. Invest Ophthalmol Vis Sci 1979;18:893-912.
24. Enoch JM, Williams RA, Essock EA Barricks M. Hyperacuity perimetry. Assessment of macular function through ocular opacities. Arch Ophthalmol 1984;102:1164-8.
25. Baraldi P, Enoch JM, Raphael S. Vision through nuclear and posterior subcapsular cataract. Int Ophthalmol 1986;9:173-8.
26. Lakshminarayanan V, Aziz S, Enoch JM. Variation of the hyperacuity gap function with age. Optom Vis Sci 1992;69: 423-6.